Effect of fluvoxamine on the pharmacokinetics of quinidine

European Journal of Clinical Pharmacology

Volumn 55, Issue 6, 1999, Pages 451-456

  Damkier, P ^a   Hansen, L L ^a   Brosen K ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Drug metabolism; Fluvoxamine; Quinidine

Indexed keywords

BIOLOGICAL MARKER; CAFFEINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; HYDROCORTISONE; KOFFEIN; MEPHENYTOIN; QUINIDINE; QUINIDINE SULFATE; SPARTEINE; SPARTEINE SULFATE; TOLBUTAMIDE; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ARTICLE; DRUG CLEARANCE; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANTI-ARRHYTHMIA AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; FLUVOXAMINE; HUMANS; MALE; METABOLIC CLEARANCE RATE; QUINIDINE; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0032772669     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050655     Document Type: Article

References (42)

1. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423
2. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS (1989) Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Invest 83: 688-697
3. Thummel KE, Shen DD, Podoll TD, et al. (1994) Use of midazolam as a human cytochrome P450 3A probe: I. in vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 271: 549-556
4. Ged C, Rouillon JM, Pichard L, et al. (1989) The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 28: 373-387
5. Watkins PB, Turgeon DK, Saenger P, et al. (1992) Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 52: 265-273
6. Kinirons MT, O'Shea D, Downing TE, et al. (1993) Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 54: 621-629
7. Darbar D, Dell'Orto S, Morike K, Wilkinson GR, Roden DM (1997) Dietary salt increases first-pass elimination of oral quinidine. Clin Pharmacol Ther 61: 292-300
8. Ochs HR, Greenblatt DJ, Woo E (1980) Clinical pharmacokinetics of quinidine. Clin Pharmacokinet 5: 150-168
9. Carroll FI, Smith D, Wall ME (1974) Carbon-13 magnetic resonance study. Structure of the metabolites of orally administered quinidine in humans. J Med Chem 17: 985-987
10. Beermann B, Leander K, Lindstrom B (1976) The metabolism of quinidine in man: structure of a main metabolite. Acta Chem Scand B 30:465
11. Drayer DE, Lowenthal DT, Restivo KM, Schwartz A, Cook CE, Reidenberg MM (1978) Steady-state serum levels of quinidine and active metabolites in cardiac patients with varying degrees of renal function. Clin Pharmacol Ther 24: 31-39
12. Leroyer R, Varoquaux O, Advenier C, Pays M (1990) Quinidine oxidative metabolism. Identification and biosynthesis of quinidine 10,11-dihydrodiol stereoisomers. Biomed Chromatogr 4: 61-64
13. Rakhit A, Holford NH, Guentert TW, Maloney K, Riegelman S (1984) Pharmacokinetics of quinidine and three of its metabolites in man. J Pharmacokinet Biopharm 12: 1-21
14. Edwards DJ, Axelson JE, Visco JP, vanEvery S, Slaughter RL, Lalka D (1987) Lack of effect of smoking on the metabolism and pharmacokinetics of quinidine in patients. Br J Clin Pharmacol 23: 351-354
15. Guengerich FP, Muller Enoch D, Blair IA (1986) Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 30: 287-295
16. Nielsen TL, Rasmussen BB, Flinois J-P, Beaune P, Brosen K (1999) In vitro metabolism of quinidine: the (3S)-3-hydroxylation is a specific marker reaction for cytochrome P4503A4 activity in human liver microsomes. J Pharmacol Exp Ther 289: 31-37
17. Jeppesen U, Rasmussen BB, Brosen K (1997) Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. Clin Pharmacol Ther 62: 279-286
18. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S (1993) Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45: 1211-1214
19. Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA (1997) Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther 62: 365-376
20. Nielsen F, Nielsen KK, Brosen K (1994). Determination of quinidine, dihydroquinidine, (3S)-3-hydroxyquinidine and quinidine N-oxide in plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 660: 103-110
21. Veronese ME, Miners JO, Randles D, Gregov D, Birkett DJ (1990) Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 47:403-411
22. Vinks A, Inaba T, Otton SV, Kalow W (1982) Sparteine metabolism in Canadian Caucasians. Clin Pharmacol Ther 31: 23-29
23. Sanz EJ, Villen T, Alm C, Bertilsson L (1989) S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 45: 495-499
24. Rasmussen BB, Brosen K (1997) Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans. Br J Clin Pharmacol 43: 253-258
25. Fuhr U, Rost KL, Engelhardt R, et al. (1996) Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 6: 159-176
26. Lykkesfeldt J, Loft S, Poulsen HE (1994) Simultaneous determination of urinary free cortisol and 6 beta-hydroxycortisol by high-performance liquid chromatography to measure human CYP3A activity. J Chromatogr B Biomed Sci Appl 660: 23-29
27. Wacher VJ, Wu CY, Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13: 129-134
28. Emi Y, Tsunashima D, Ogawara K, Higaki K, Kimura T (1998) Role of P-glycoprotein as a secretory mechanism in quinidine absorption from rat small intestine. J Pharm Sci 87: 295-299
29. Kusuhara H, Suzuki H, Terasaki T, Kakee A, Lemaire M, Sugiyama Y (1997) P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier. J Pharmacol Exp Ther 283: 574-580
30. Kashuba ADM, Nafziger AN, Kearns GL, et al. (1998) Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6 and CYP3A as determined by phenotyping. Clin Pharmacol Ther 64: 257-268
31. Von ML, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI (1995) Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 15: 125-131
32. Rasmussen BB, Maenpaa J, Pelkonen O, et al. (1995) Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 39: 151-159
33. von Moltke LL, Greenblatt DJ, Harmatz JS, et al. (1996) Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276: 370-379
34. Back DJ, Tjia JF (1991) Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 32: 624-626
35. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI (1994) In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 34: 1222-1227
36. Fleishaker JC, Hulst LK (1994) A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 46: 35-39
37. Kivisto KT, Kroemer HK (1997) Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 37: 40-48
38. Vozeh S, Uematsu T, Guentert TW, Ha HR, Follath F (1985) Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects. Clin Pharmacol Ther 37: 575-581
39. Brosen K, Davidsen F, Gram LF (1990) Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man. Br J Clin Pharmacol 29: 248-253
40. Hardy BG, Schentag JJ (1988) Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance. Int J Clin Pharmacol Ther Toxicol 26: 388-391
41. Spigset O, Granberg K, Hagg S, Norstrom A, Dahlqvist R (1997) Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. Eur J Clin Pharmacol 52: 129-133
42. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE (1992) The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34: 262-265